Daiichi Sankyo’s Value Creation Process

Introduction

Daiichi Sankyo is requested from society for various needs including providing a stable supply of quality pharmaceuticals, responding to unmet medical needs*, improving access to pharmaceuticals**, and ESG activities. We engage in medium-to-long-term initiatives using our financial capital, intellectual capital, human capital and other capitals to enhance our long-term corporate value, as well as to realize a sustainable society.

At Daiichi Sankyo, we define our 2025 Vision as striving to become a “Global Pharma Innovator with competitive advantage in oncology,” and we are currently aiming to achieve the goals in our 5-Year Business Plan in order to realize this vision. The basis of Daiichi Sankyo’s value creation is in addressing diverse medical needs through continually creating innovative pharmaceuticals while taking advantage of our strengths in science and technology, global organization and talent, as well as our presence in Japan. At the same time, we address sustainability issues including social and the environmental issues, integrally with our business activities, and these activities also deliver value to society.

By continuing this cycle of our value creation process, we will sustainably improve our corporate value, and we will provide the values in a well-balanced manner generated by Daiichi Sankyo to our stakeholders and society, including patients, their families, healthcare professionals, our shareholders and investors, business partners, employees and local communities.

* Medical needs for effective treatment and drugs yet to be developed
** Pharmaceuticals needed by patients being delivered sufficiently and consistently